eligibility_summary
Eligible: Women 18–70 with newly diagnosed locally advanced breast cancer (stage IIIb–IIIc), clinically or biopsy confirmed, deemed resectable, and receiving surgery, radiotherapy, and chemotherapy, consent and agree to follow-up with QoL and mood assessments. Exclude: prior BC therapy, not candidates for standard treatment, other malignancy, pregnancy/lactation, active infection/fever, or serious comorbidities affecting compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Randomized controlled trial in locally advanced breast cancer comparing surgery→systemic therapy vs neoadjuvant therapy→surgery→systemic therapy. Interventions: modified radical mastectomy, chemotherapy—doxorubicin (anthracycline, DNA intercalation/topoisomerase II inhibition, ROS), paclitaxel and nab‑paclitaxel (taxanes, microtubule stabilization/mitotic arrest), cyclophosphamide (alkylating, DNA crosslinking), endocrine therapy—toremifene (SERM, ER blockade), goserelin/Zoladex (GnRH agonist, ovarian suppression), aromatase inhibitors (CYP19 inhibitors, ↓estrogen synthesis), targeted therapy—trastuzumab (anti‑HER2 mAb, blocks signaling, ADCC), pertuzumab (anti‑HER2 mAb, prevents HER2/HER3 dimerization, ADCC), radiotherapy (ionizing radiation, DNA double‑strand breaks). Targets/pathways: rapidly dividing tumor cells, DNA replication/repair, microtubules/mitosis, ER signaling and HPG axis, aromatase pathway, HER2–PI3K/AKT/MAPK signaling, immune‑mediated ADCC, local tumor control by radiation.